Form 4 for CNSP CNS Pharmaceuticals, Inc.

Accepted 2022-01-25 00:00:00 ET · period of report 2020-05-05 · accession 0001683168-22-000460 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2022-01-25	2020-05-05	CNSP	Priebe Waldemar	10%	J - Other	—	-1.50M	7.53M	-17%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2020-05-05	J	D	1,495,867	—	7,533,133	I See footnote	—	—	(F1) The shares are held by a limited liability company for which the reporting person's adult child is the sole manager and adult children are sole members. Prior to May 5, 2020, the reporting person was a manager of the limited liability company. The reporting person ceased to be a manager of the limited liability company on May 5, 2020, and since such date has not had any voting or dispositive power over the shares held by the limited liability company. The reporting person has never had a pecuniary interest in the limited liability company. (F2) Consists of: (i) 7,333,133 shares of common stock held by a limited liability company; and (ii) 200,000 shares held by Houston Pharmaceuticals, Inc.